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Abstract 
Background: Evidence from observational comparative effectiveness research (CER) is ranked below that from 
randomized controlled trials in traditional evidence hierarchies. However, asthma observational CER studies represent 
an important complementary evidence source answering different research questions and are particularly valu-
able in guiding clinical decision making in real-life patient and practice settings. Tools are required to assist in quality 
appraisal of observational CER to enable identification of and confidence in high-quality CER evidence to inform 
guideline development.
Methods: The REal Life EVidence AssessmeNt Tool (RELEVANT) was developed through a step-wise approach. We 
conducted an iterative refinement of the tool based on Task Force member expertise and feedback from pilot testing 
the tool until reaching adequate inter-rater agreement percentages. Two distinct pilots were conducted—the first 
involving six members of the Respiratory Effectiveness Group (REG) and European Academy of Allergy and Clinical 
Immunology (EAACI) joint Task Force for quality appraisal of observational asthma CER; the second involving 22 mem-
bers of REG and EAACI membership. The final tool consists of 21 quality sub-items distributed across seven method-
ology domains: Background, Design, Measures, Analysis, Results, Discussion/Interpretation, and Conflict of Interest. 
Eleven of these sub-items are considered critical and named “primary sub-items”.
Results: Following the second pilot, RELEVANT showed inter-rater agreement ≥ 70% for 94% of all primary and 93% 
for all secondary sub-items tested across three rater groups. For observational CER to be classified as sufficiently high 
quality for future guideline consideration, all RELEVANT primary sub-items must be fulfilled. The ten secondary sub-
items further qualify the relative strengths and weaknesses of the published CER evidence. RELEVANT could also be 
applicable to general quality appraisal of observational CER across other medical specialties.
Conclusions: RELEVANT is the first quality checklist to assist in the appraisal of published observational CER devel-
oped through iterative feedback derived from pilot implementation and inter-rater agreement evaluation. Developed 
for a REG-EAACI Task Force quality appraisal of recent asthma CER, RELEVANT also has wider utility to support appraisal 
of CER literature in general (including pre-publication). It may also assist in manuscript development and in educating 
relevant stakeholders about key quality markers in observational CER.
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Background
Asthma affects an estimated 334 million people world-
wide, 14% of the world’s children and 8.6% of young 
adults [1]. With such high global prevalence, the 
affected patient population is inevitably broad and het-
erogeneous. Such heterogeneity is observed through 
level of asthma control, severity, various marker pheno-
types, and asthma treatment. However, there remains 
unknown precipitants of future impairment and risk. 
Healthcare professionals need informed clinical guide-
lines to help support decision making and to tailor 
management approaches to the complex needs of the 
diverse range of patients seen in clinical practice.
Current asthma guidelines are developed by experts 
with the goal of signposting evidence-based approaches 
that will optimize patient outcomes. Their recommen-
dations are based on a synthesis of the available litera-
ture and (reflecting traditional evidence hierarchies) 
rely heavily on classical randomized controlled tri-
als (RCTs). RCTs have relatively high internal validity 
and the ability to clearly establish a causal relationship 
between an exposure and an outcome [2]. This high 
internal validity is achieved through selective patient 
inclusion and highly-controlled ecologies of care. How-
ever, it also limits RCTs’ external validity and their rel-
evance to real-world care and many routine clinical 
scenarios [3, 4]. In everyday practice, healthcare pro-
fessionals often encounter complex clinical, lifestyle, 
psychosocial, demographic and attitudinal factors; 
aspects of the real world that are excluded as much as 
possible within RCTs to maximize their internal valid-
ity. The clinical implications of these factors are better 
addressed through real-life research methodologies—
observational studies, pragmatic trials, observational 
comparative effectiveness research (CER)—which, by 
design, reflect true ecologies of care and include fac-
tors such as gradations of disease severity, diverse 
patient demographics, comorbid conditions, treatment 
adherence and patients’ lifestyles. Thus, the questions 
addressed through RCT and CER research are related 
yet distinct, each having importance toward improv-
ing patients’ health. The integration of robust evidence 
from both RCTs and real-life CER can provide a more 
complete picture of outcomes in complex clinical sce-
narios. A combination of evidence sources better repre-
sents the totality of an intervention’s effectiveness and 
guidelines based on such evidence combinations are 
more applicable to real-world clinical practice and its 
many and varied associated challenges.
Calls for better integration of a range of evidence 
sources to inform more holistic respiratory guidelines 
[5–7] will only be realized if confidence in non-RCT 
evidence is increased. Inherent difficulties in assessing 
whether real-life evidence is of sufficient quality to be 
considered within the context of clinical guidelines has 
been a barrier to acceptance. Development of a system-
atic and implementable approach to real-life CER qual-
ity appraisal is an important step towards implementing 
this necessary paradigm shift. Responding to this need, 
the Respiratory Effectiveness Group (REG) and European 
Academy of Allergy and Clinical Immunology (EAACI) 
formed a joint task force to conduct a quality appraisal 
of the published observational asthma CER literature 
and, in order to do so, worked systematically to develop 
a standardized tool for CER quality appraisal (Additional 
file 1: Fig. 1).
This paper outlines the methodology and process 
that lead to the development of the REal Life EVidence 
AssessmeNt Tool (RELEVANT). The tool was created to 
assist the Task Force in identifying CER studies of suffi-
ciently high quality to warrant consideration by asthma 
guideline bodies [8].
Methods
RELEVANT was developed across six key phases 
between June 2014 and September 2015, including a lit-
erature review and synthesis of the existing literature 
followed by iterative processes for creating a novel tool 
(Fig. 1).
Phase I: Review of the quality assessment literature
Seeking to integrate the Task Force work within existing 
quality appraisal activities, a number of publications on 
quality parameters for non-RCT CER were first identi-
fied and reviewed [9–14]. The principles of these publi-
cations were chiefly incorporated within two key papers 
published in 2014—Berger et  al. [14] and Roche et  al. 
[13]—which jointly formalize the CER nomenclature and 
offer recommendations for systematic quality appraisal of 
observational database studies. Roche et al. [13]—Quality 
criteria for observational database comparative studies—
was a literature-based proposal published by members 
of REG offering suggestions for the quality appraisal of 
observational database studies with a particular focus on 
respiratory medicine. Berger et  al’s [14] Good Practice 
Task Force Report was developed to evaluate the qual-
ity of pharmaceutical outcomes research evidence and 
was published on behalf of the International Society For 
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Fig. 1 Six key development phases of RELEVANT
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Pharmacoeconomics and Outcomes Research (ISPOR), 
Academy of Managed Care Pharmacy (AMCP) and the 
National Pharmaceutical Council (NPC). It involved a 
review of the current literature on reporting standards 
for outcomes research published prior to 2014 and pro-
posed a number of study design criteria to assist in the 
assessment of CER within the context of informing 
healthcare decision making. These two papers were used 
to identify the quality domains and critical sub-items of 
these domains that the REG–EACCI Task Force mem-
bers should incorporate in RELEVANT.
Phase II: Initial tool creation
The RELEVANT quality domains and sub-items were 
identified by mapping the components both unique and 
common to the Berger [14] and Roche [13] publications. 
The mapping enabled a broad net to be cast such that all 
domains and quality sub-items were captured while also 
enabling identification of areas of agreement (core con-
cepts) and redundancies (for elimination).
A structured taxonomy was developed such that design 
categories common to both papers were defined as qual-
ity “Domains” and within these were labeled “sub-items” 
(markers of methodological quality).
Phase III: Rotterdam task force review and feedback
The checklist produced (Additional file  2: Table  1) was 
reviewed and discussed by Task Force members at a face-
to-face meeting as part of the REG Summit (Rotterdam, 
the Netherlands) in January 2015. The central recom-
mendation was to reduce the number of items in the tool 
to minimize potential inter-rater variability. It was also 
agreed that all Task Force members would, remotely and 
independently, review the individual quality sub-items 
within the checklist and advise whether sub-items should 
be kept, removed or merged and the rationale for their 
recommendation. This feedback was used to item-reduce 
the checklist for initial pilot testing by Task Force mem-
bers (Table 1).
Phase IV: Pilot application of the quality assessment tool
To pilot the tool and assess inter-rater variability, six 
papers from the Task Force’s literature review were 
randomly assigned for appraisal to two Task Force 
subgroups of nine members, Group A (n = 3 papers 
[15–17]) and Group B (n = 3 [18–20]). Three of the 
papers reviewed considered the relationship between 
adherence and asthma outcomes, and three the relation-
ship between particle size or device type and outcomes. 
Participant Task Force members were not permitted to 
appraise papers that they had co-authored; papers were 
otherwise randomly allocated and reviews carried out 
independently.
Inter-rater variability also described as % rater agree-
ment, was evaluated as the percentage concordance 
among raters at the individual sub-item, pooled primary 
sub-item, pooled secondary sub-item and combined pri-
mary/secondary sub-item level. For example, for a given 
sub-item, if four of the five raters deemed this sub-item 
as a “yes” whereas the remaining one rater deemed this 
sub-item as a “no,” then the inter-rater variability (% rater 
agreement) would be 4/5 = 80%. A percentage agree-
ment that approaches 50% suggests large disagreement 
that is no better than chance whereas % agreement that 
approaches 100% suggests strong and full concordance 
across raters. Raters were invited to provide written feed-
back on usability of the checklist and to identify areas of 
difficulty in criterion interpretation or application. Poten-
tial areas of divergent interpretation were also explored 
through interactive discussion with two members of 
Group A to understand the rationale for their differences 
in opinions where they occurred.
The Task Force members next met at the American 
Thoracic Society Conference in May 2015 (Denver, Colo-
rado, USA) to review the pilot results and enact neces-
sary revisions. Inter-rater agreement was calculated and 
qualitative feedback invited from participating raters 
to identify opportunities to reduce inter-rater variabil-
ity further. Redundancies in sub-items were identified 
through rater quality feedback and deleted.
Task Force rater feedback also recommended that sec-
ondary sub-items remained hidden until fulfillment of all 
the primary sub-items is confirmed in order to stream-
line the review process and avoid time being spent quali-
fying more subtle aspects of papers that may ultimately 
fail to meet the minimum requirement for guideline 
consideration.
A wider pilot of the refined checklist (Additional file 1: 
Table  2) was recommended to allow involvement of a 
larger number of raters (≥ 20) and to assess the impact 
of the implemented revisions and tool simplification on 
inter-rater agreement.
Phase V: Extended pilot
Twenty-two participants were identified for the extended 
pilot via an open invitation emailed to all REG collabora-
tors and members of EAACI (Additional file 1: Table 3). 
Six papers from the Task Force’s CER literature review 
were selected for appraisal [21–26] and assigned in pairs 
across three rater subgroups (Groups A [n = 7]; Group B 
[n = 8]; Group C [n = 7]). There were two papers on the 
relation between adherence and outcomes, two on the 
relation between persistence to therapy and healthcare 
resource utilization and two on the relation between par-
ticle size and outcomes.
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Raters were asked to review the papers independently 
and to use an Excel-based version of the tool to record 
checklist fulfillment for each paper and then to return 
these to the Task Force coordinator via email for colla-
tion. A one-page user guide was developed to ensure all 
participating raters received (or had access to) stand-
ardized instructions as to the use of the tool.
As in the earlier pilot, raters were not allowed to review 
papers they had coauthored. Allocation of papers was 
otherwise random. As before, calculation of inter-rater 
variability (percentage agreement) was defined by con-
sistent ratings (all raters scoring the same paper ‘Yes’ or 
all ‘No’) at a per-criterion level for each paper. Agreement 
results were then estimated for each paper at the item-, 
Table 1 Phase III item-reduced checklist assessed using the within-Task Force pilot
a For a retrospective design, answering “no” to this item may suggest a “fatal flaw” using the methodology developed by  ISPOR14
b For any study design, answering “no” to this item may suggest a “fatal flaw” using the methodology developed by  ISPOR14
Primary or secondary Items Score 
1 = ”yes”; 
0 = ”no”
Reviewer 
comments
Background/relevance: 3 items (1 primary, 2 secondary)
Primary 1. Clear underlying hypotheses and specific research questions
Secondary 2. Relevant population and setting
Secondary 3. Relevant interventions and outcomes are included
Design 4 items: (2 primary, 2 secondary)
Primary 1. Evidence of a priori protocol, review of analyses, statistical analysis plan, and interpretation of 
results
Primary 2. Comparison groups justified
Secondary 3. Registration in a public repository with commitment to publish results
Secondary 4. Data sources that are sufficient to support the  studya
Measures: 4 items (2 primary, 2 secondary)
Primary 1. Was exposure clearly defined, measured and (relevance)  justifiedb
Primary 2. Primary outcomes defined, measured and (relevance)  justifiedb
Secondary 3. Length of observation: Sufficient follow up duration to reliably assess outcomes of interest and 
long-term treatment effects
Secondary 4. Sample size: calculated based on clear a priori hypotheses regarding the occurrence of out-
comes of interest and target effect of studied treatment versus comparator
Analyses 3 items (1 primary, 2 secondary)
Primary 1. Thorough assessment of and mitigation strategy for potential confounders
Secondary 2. Study groups are compared at baseline and analyses of subgroups or interaction effects 
reported
Secondary 3. Sensitivity analyses are performed to check the robustness of results and the effects of key 
assumptions on definitions or outcomes
Results/reporting: 6 items (2 primary, 4 secondary)
Primary 1. Extensive presentation of results/authors describe the key components of their statistical 
 approachesa
Primary 2. Were confounder-adjusted estimates of treatment effects  reportedb
Secondary 3. Flow chart explaining all exclusions and individuals screened or selected at each stage of defin-
ing the final sample
Secondary 4. Was follow-up similar or accounted for between groups
Secondary 5. Did the authors describe the statistical uncertainty of their findings
Secondary 6. Was the extent of missing data reported
Discussion/interpretation: 4 items (2 primary, 2 Secondary)
Primary 1. Results consistent with known information or if not, was an explanation provided
Primary 2. Are the observed treatment effects considered clinically meaningful
Secondary 3. Discussion of possible biases and confounding factors, especially related to the observational 
nature of the study
Secondary 4. Suggestions for future research to challenge, strengthen, or extend the study results
Conflict of interest: (1 primary item)
Primary 1. Potential conflicts of interest, including study funding, were stated
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domain and global (all primary sub-items) level within 
each rater group and in sum across all rater groups.
The results of the pilot were reviewed by the Task Force 
members at a face-to-face meeting at the 2015 European 
Respiratory Society Conference (Amsterdam, The Neth-
erlands). Further qualitative feedback was invited from 
pilot raters to identify remaining opportunities to remove 
redundancies, potential ambiguity and associated inter-
rater variability.
The Task Force members implemented final rephrasing 
recommendations from the Phase V pilot and approved 
the tool for use for the primary Task Force CER literature 
review [8].
Phase VI: development of an online tool
To aid ease of RELEVANT implementation for the wider 
Task Force literature review [8], an online version was 
developed using Google forms. The conversion of the 
tool to an online format minimized the potential for data 
mis-entry and incomplete data capture by use of drop 
down lists and questionnaire logic.
Results
Initial tool creation (Phase I–III)
Mapping the quality recommendations within the pri-
mary reference papers Berger et al. [14] and Roche et al. 
[13] resulted in an initial 43-item checklist (Additional 
file 2: Table 1). Implementation of the Task Force mem-
bers’ recommendations for item-reduction narrowed 
the tool items to 25 quality sub-items distributed across 
seven core quality domains (Table 1).
Tool appraisal and item reduction (Phases IV and V)
Evaluation of inter-rater agreement of the initial tool 
indicated wide variation (50–100%) in concordance 
across individual sub-items: < 60% for 8 of 25 sub-items; 
60–67% for 10 of 25 sub-items and ≥ 80% for 7 of 25 sub-
items. Domain-level agreement was similarly varied (50–
100%). The qualitative feedback suggested this variation 
was largely driven by differences in semantic interpre-
tation of some of the sub-items and could be addressed 
by further removal of any redundancies and careful 
rephrasing and further, e.g. eliminating subjective words 
(replacing “relevant” with “justified”) and splitting “dou-
ble-headed” sub-items into separate, discrete sub-items.
The 22 raters involved in the extended pilot came from 
a wide range of countries (> 10) and included members 
of the REG collaborator group, EAACI Asthma Sec-
tion Members, Global Initiative for Chronic Obstructive 
Lung Disease, Global Initiative for Asthma, the American 
Thoracic Society and the European Respiratory Soci-
ety (Additional file  1: Table  3). Inter-rater agreement of 
the version of the tool used for the extended pilot found 
concordance in excess of 70% for 94% of primary sub-
items and 93% of secondary sub-items (Table  2). When 
compared across the 3 groups (A–C), agreement on 
the primary quality sub-items varied from 64–100% to 
55–100% for secondary sub-items.
Qualitative feedback from the pilot raters identified 
some remaining sub-items in the tool that could be fur-
ther simplified to reduce potential inter-rater variability. 
Raters frequently commented on the ease of use of the 
tool, but noted the recurrent challenge of a lack of neces-
sary information in the papers under appraisal. The Task 
Force members implemented the final rephrasing recom-
mendations and finalized the checklist, with 21 items, as 
“RELEVANT” (Table 3).
RELEVANT
The final tool—RELEVANT—guides systematic appraisal 
of the quality of published observational CER papers 
across seven domains: Background, Design, Measures, 
Analysis, Results, Discussion/Interpretation, Conflicts of 
Interest (Table 3). Raters must indicate fulfillment (Yes/
No) of 11 quality sub-items across these seven domains, 
e.g. Background (Domain 1), Criterion 1.1: “Clearly 
stated research question” (Yes/No); Conflicts of Interest 
(Domain 7), Criterion 7.1: “Potential conflicts of inter-
est, including study funding, are stated” (Yes/No). “REL-
EVANT quality” is defined as fulfillment of all 11 primary 
sub-items. Failure to meet any one primary criterion 
reflects a potential “fatal flaw” in a study’s design or, if 
failure reflects absence of the necessary detail, a lack of 
sufficient transparency in reporting. A fatal flaw is a con-
cept defined by Berger et al. as an aspect of the: “design, 
execution, or analysis elements of the study that may 
significantly undermine the validity of the results [14]. 
If all primary sub-items are fulfilled, assessment of ten 
additional, secondary, parameters is prompted to enable 
further characterization of the relative strengths and 
weaknesses of the paper [8].
Discussion
This is the first practical tool specifically developed to 
assist in the appraisal of published observational CER 
with the purpose of informing asthma guidelines and 
supporting decision-makers. Rater agreement was 
assessed in two pilots with the second, broader pilot 
returning robust results, reflecting the value of using 
Task Force expertise and early pilot rater feedback to 
revise the tool iteratively. We acknowledge that other 
tools such as the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) exist for 
rating the quality of the best available evidence [2]. 
However, existing tools such as GRADE automatically 
downgrade observational study designs and upgrade 
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randomized designs with the primary intent toward 
informing the quality of efficacy signals. The purpose 
of RELEVANT is more specific in that it focuses on 
observational CER studies that can potentially inform 
asthma guidelines and decision-makers. Further, REL-
EVANT attempts to weigh the benefits and harms of 
internal versus external validity, a domain lacking from 
GRADE and other tools that prioritize randomized 
designs and efficacy signals. Thus, within the specific 
case of real-world effectiveness study quality, broad 
tools that emphasize efficacy may not be fit for purpose.
RELEVANT enables quality appraisal of the pub-
lished literature and so complements existing quality 
checklists, which have traditionally focused on quality 
markers for protocol and manuscript development and 
from a largely empirical (rather than practical/applied) 
perspective. Initial drafts of the tool used wording from 
the previous quality assessment literature, but the pilot 
work revealed the potential for misinterpretation unless 
very precise language was used and each criterion had a 
singular and specific focus. Refer to the Roche and col-
leagues companion manuscript for clinical applications 
and evaluations that use the RELEVANT tool [8].
RELEVANT was developed to assist clinical experts 
and guideline developers in appraising observational 
asthma CER study quality. Used in combination with 
Table 2 Extended Pilot Item level agreement summary
Group A
(%)
Group B
(%)
Group C
(%)
a: Agreement across primary sub-items
1. Background 1.1. Clearly stated research question 79 100 86
2. Design 2.1. Population defined and justified 64 94 71
2.2. Comparison groups defined and justified 93 71 79
2.3. Setting defined and justified 93 100 93
3. Measures 3.1. (If relevant), exposure is clearly defined 93 71 76
3.2. Primary outcomes clearly defined and measured 71 89 93
4. Analysis 4.1. Potential confounders are considered and adjusted for in the analysis, and reported 64 81 71
4.2. Study groups are compared at baseline 79 79 79
5. Results 5.1. Results are clearly presented for all primary and secondary endpoints as well as 
confounders
79 94 71
6. Discussion/interpretation 6.1. Results consistent with known information or if not, an explanation is provided 86 100 86
6.2. The clinical relevance of the results is discussed 85 88 93
7. Conflict of interests 7.1. Potential conflicts of interest, including study funding, are stated 79 100 93
b: Agreement across secondary quality sub-items
1. Background 1.1. The research is based on a review of the background literature (ideal standard is a 
systematic review, but minimally citation of multiple [≥ 1] references in the introduc-
tion
88 100 100
2. Design 2.1. Clear written evidence of a priori protocol development and registration (e.g. in 
ENCePP or Clinicaltrials.gov online registries) and a priori statistical analysis plan
100 73 83
2.2. The data source (or database), as described, contains adequate exposures (if rel-
evant) and outcome variables to answer the research question
88 100 100
3. Measures 3.1. Sample size justifies the inclusion criteria and follow-up period for the primary 
outcome
88 71 88
4. Analysis No secondary item NA NA NA
5. Results 5.1. Flow chart explaining all exclusions and individuals screened or selected at each 
stage of defining the final sample
100 83 75
5.2. Was follow-up similar or accounted for between groups (i.e. no unexplained dif-
ferential loss to follow up)
100 55 58
5.3. The authors describe the statistical uncertainty of their findings (e.g. p-values, 
confidence intervals)
100 100 83
5.4. The extent of missing data is reported 75 88 100
6. Discussion/interpretation 6.1. Possible biases and/or confounding factors described 100 100 83
6.2. Suggestions for future research provided (e.g. to challenge, strengthen, or extend 
the study results)
100 63 58
7. Conflict of interests No secondary item NA NA NA
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other tools such as the GRADE, RELEVANT can help 
facilitate critical appraisal of observational studies as 
well as pragmatic trials and so contribute to a broader 
appraisal of the available asthma evidence base. It is a 
time efficient and user-friendly method of quality assess-
ment and has potential utility as a teaching aid, manu-
script development guide or as a tool for use by journal 
peer reviewers. Indeed, any researcher or clinician with 
the ability to critically read CER (e.g. basic knowledge 
of confounding in observational research) should find 
the tool self-explanatory and potentially useful as a pub-
lication checklist as well as a framework for literature 
appraisal.
RELEVANT development was an ancillary (although 
necessary) step towards completion of the original Task 
Force’s objective of conducting a quality appraisal of the 
observational asthma CER literature. As such, a quasi-
pragmatic rather than entirely systematic and externally 
validated approach was taken. All primary and secondary 
sub-items featured in the tool were felt to be important 
(within the literature and by Task Force members), but 
expert opinion was used to differentiate between primary 
(mandatory) and secondary (complementary) sub-items 
to ensure RELEVANT was comprehensive but also rela-
tively concise to aid in successful practical implementa-
tion. The final categorization was based on frequency of 
reference within the prior literature and on Task Force 
member consensus judgment. Prioritization and catego-
rization of the primary/secondary sub-items within the 
checklist could be revisited and adapted for other pur-
poses, as appropriate.
While RELEVANT is intended as a tool to assist in 
the quality appraisal of observational CER, RELEVANT 
assessments are influenced by the quality of reporting of 
the research as much as the by the inherent quality of the 
study itself. While this may result in an under-estimation 
of the quality of the published work (e.g. dismissal of a 
paper owing to a failure in reporting rather than in the 
research methodology) the Task Force members felt this 
was unavoidable. An alternative approach could involve 
Table 3 RELEVANT quality domains: primary sub-items (critical to  satisfy minimum guideline requirements) 
and secondary sub-items (enabling further descriptive appraisal)
Quality domains and sub-items Fulfilled
(Y/N)
Primary sub-items
1. Background 1.1. Clearly stated research question
2. Design 2.1. Population defined
2.2. Comparison groups defined and justified
3. Measures 3.1. (If relevant), exposure (e.g. treatment) is clearly defined
3.2. Primary outcomes defined
4. Analysis 4.1. Potential confounders are addressed
4.2. Study groups are compared at baseline
5. Results 5.1. Results are clearly presented for all primary and secondary endpoints as well as confounders
6. Discussion/interpretation 6.1. Results consistent with known information or if not, an explanation is provided
6.2. The clinical relevance of the results is discussed
7. Conflict of interests 7.1. Potential conflicts of interest, including study funding, are stated
Secondary sub-items
1. Background 1.1. The research is based on a review of the background literature (ideal standard is a systematic review)
2. Design 2.1. Evidence of a priori design, e.g. protocol registration in a dedicated website
2.2. Population justified
2.3. The data source (or database), as described, contains adequate exposures (if relevant) and outcome vari-
ables to answer the research question
2.4. Setting justified
3. Measures 3.1 Sample size/Power pre-specified
4. Analysis No secondary item NA
5. Results 5.1. Flow chart explaining all exclusions and individuals screened or selected at each stage of defining the final 
sample
5.2. The authors describe the statistical uncertainty of their findings (e.g. p values, confidence intervals)
5.3. The extent of missing data is reported
6. Discussion/interpretation 6.1. Possible biases and/or confounding factors described
7. Conflict of interests No secondary item NA
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contacting each author group and offering them the 
opportunity to provide more information where a quality 
limitation resulted from a lack of available data, but there 
was insufficient Task Force resources available to permit 
this approach. This emphasizes the need for accurate and 
comprehensive reporting and the interest of protocol 
registration.
While development of RELEVANT sought to remove 
subjective interpretation of the quality sub-items, the 
rater’s appraisal of the fulfillment of the quality markers 
is unavoidably open to rater opinion and judgment. In 
turn, the appropriateness of such judgment is inherently 
affected by raters’ experience and expertise with respect 
to observational CER. The majority of raters involved 
in the pilot work, however, were members of REG—a 
group that has a particular focus on real-life research 
methods—and so most participating raters would have 
had substantial prior knowledge and/or involvement in 
CER. This may have contributed to the high inter-rater 
agreement recorded especially during the extended pilot 
testing.
There is a need for moderation in the recommended 
potential uses of the checklist tool to avoid it being 
widely adopted for purposes other than those for which 
it was designed. However, there are also potential oppor-
tunities to use the tool in training exercises to educate 
fellows, journals editors and reviewers as to what consti-
tutes quality in CER. If the tool were introduced within 
graduate-level training, it may also have the potential to 
help shape and inform the design of more appropriate 
observational CER in the future.
Conclusions
RELEVANT is a user-friendly quality appraisal tool com-
prising 21 quality sub-items (11 primary; 10 secondary) 
across seven core quality domains. It was developed to 
support quality review of observational asthma CER for 
the purposes of the joint REG-EAACI Task Force lit-
erature review, but is also now used among Task Force 
members to support their peer review activities for res-
piratory journals and to guide the development of their 
own research papers. It is the first of its kind to support 
quality appraisal of published research and to have been 
developed through iterative feedback derived from pilot 
implementation and inter-rater agreement evaluation.
RELEVANT can be downloaded in Excel or pdf format 
from the REG [27] and EAACI [28] websites for use by 
guideline developers, researchers, medical writers, and 
other interested parties. Further, a RELEVANT tool user 
guide can be downloaded on the REG website [27].
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